Nephrology

MYH9 gene variations help explain high rate of kidney disease in African-Americans

of Medicine in Baltimore, MD, who will introduce the press briefing. In September, researchers from the National Institutes of Health (NIH) in Bethesda, MD, and Johns Hopkins University published independent studies showing...

Unlike African-Americans In US, African-American Canadians Who Receive Kidney Transplants Do Not...

African American kidney disease patients in both Canada and the United States are less likely than Caucasian Americans to have access to kidney transplants, but only African-Americans in the United States have worse health...

Serum Uric Acid and Endothelial Dysfunction in Continuous Ambulatory Peritoneal Dialysis Patients

Ziyong Tanga, Li-Tao Chenga, Hong-Yan Lia, b, Tao Wanga aDivision of Nephrology, Peking University Third Hospital, Beijing, and bDivision of Nephrology, Zhengzhou University First Affiliated Hospital, Zhengzhou, China Abstract...

Watson Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript

October 29, 2008 | about stocks: Executives Patty Eisenhaur - Also present and available during the Q&A portion of the call are Tom Resillo, President of our Generics Division, Ed Heimers, President of our Brand Division, Al...

African-American Canadians who receive kidney transplants fare better than those in US

African American kidney disease patients in both Canada and the United States are less likely than Caucasian Americans to have access to kidney transplants, but only African-Americans in the United States have worse health...

Questcor Pharmaceuticals Evaluating Acthar(r) Gel as a Potential New Treatment for Kidney Disorder

Tuesday October 28, 6:00 am ET Nephrotic Syndrome Already An Approved Indication for Acthar Key Nephrology Experts Have Shown Interest in Acthar as a Potential New Therapy; Patient Enrollment for First Study Expected to Begin...

Questcor Pharmaceuticals Evaluating Acthar(r) Gel as a Potential New Treatment for Kidney Disorder

UNION CITY, Calif., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) today announced that it has identified Nephrotic Syndrome as a potential new therapeutic area for its principal product H.P....

Questcor Pharmaceuticals Evaluating Acthar(r) Gel as a Potential New Treatment for Kidney Disorder

UNION CITY, Calif., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) today announced that it has identified Nephrotic Syndrome as a potential new therapeutic area for its principal product H.P....

Questcor Pharmaceuticals Evaluating Acthar(R) Gel As a Potential New Treatment for Kidney Disorder

Nephrotic Syndrome Already An Approved Indication for Acthar Key Nephrology Experts Have Shown Interest in Acthar as a Potential New Therapy; Patient Enrollment for First Study Expected to Begin in First Quarter of 2009 UNION...

Questcor Pharmaceuticals Evaluating Acthar Gel as a Potential New ...

The Company is also developing QSC-001, a unique orally disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain. ... (Tue Oct 28 05:48:29 2008...